证券代码：688212 证券简称：澳华内镜 公告编号：2025-045 上海澳华内镜股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/6/17 | 2025/6/18 | 2025/6/18 | 一、通过分配方案的股东大会届次和日期 本次利润分配方案经上海澳华内镜股份公司（以下简称 "公司"）2025 年 5 月 8 日的2024年年度股东大会审议通过。 二、分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东 （公司回购专用证券账户中的股份除外）。 根据《中华人民共和国公司法》《中华人民共和国证券法》《上海证券交易所 是否涉及差异化分红送转：是 每股分配比例 每股现金红利0.08元（含税） 相关日期 1. 发放年度：2024年年度 2. 分派对象： 上市公司 ...

Group 1 - The core viewpoint of the article highlights the performance of the Shanghai Stock Exchange Sci-Tech Innovation Board Medical Index, which reflects the overall performance of up to 30 listed companies in the medical sector on the Sci-Tech Innovation Board [1] - The Shanghai Sci-Tech Innovation Board Medical Index has increased by 2.43% in the past month, decreased by 2.53% in the past three months, and has risen by 1.89% year-to-date [1] - The index is based on a reference date of December 30, 2022, with a base point of 1000.0 [1] Group 2 - The top ten weighted companies in the index include: Huatai Medical (10.99%), United Imaging (10.25%), Aibo Medical (6.82%), Yirui Technology (6.61%), Nanwei Medical (5.29%), Shengxiang Biology (5.01%), Xinmai Medical (4.65%), Haier Biomedical (4.17%), Aohua Endoscopy (3.77%), and Yahui Long (3.65%) [1] - The index's holdings are entirely composed of companies listed on the Shanghai Stock Exchange, with a 100% allocation [1] - In terms of industry composition, medical consumables account for 44.80%, medical devices for 33.62%, and in vitro diagnostics for 21.58% [1] Group 3 - The index samples are adjusted quarterly, with adjustments implemented on the next trading day following the second Friday of March, June, September, and December [2] - Weight factors are generally fixed until the next scheduled adjustment, with special circumstances allowing for temporary adjustments [2] - Companies that are delisted or undergo mergers, acquisitions, or splits will be handled according to the calculation and maintenance guidelines [2]

Group 1 - The report provides a comprehensive analysis of the global high-definition electronic bronchoscope market, including market trends, growth forecasts, and competitive landscape [2][3][4] - The market is segmented by product type, application, and region, with detailed sales revenue growth trends projected from 2020 to 2031 [3][4][5] - The report highlights the current status and future development trends of the high-definition electronic bronchoscope industry, indicating a positive growth trajectory [3][4][8] Group 2 - Global sales revenue for different product types of high-definition electronic bronchoscopes is expected to show significant growth, with specific CAGR figures provided for 2020, 2024, and 2031 [3][4][5] - The report outlines the supply and demand dynamics of the high-definition electronic bronchoscope market, including production capacity, output, and utilization rates from 2020 to 2031 [4][5][6] - Regional analysis indicates varying growth rates and market shares for high-definition electronic bronchoscopes across North America, Europe, China, Japan, Southeast Asia, and India [4][5][6] Group 3 - Major manufacturers in the high-definition electronic bronchoscope market are analyzed, including their production capacities, sales volumes, and revenue rankings for 2024 [4][5][6] - The competitive landscape is characterized by a concentration of market share among top manufacturers, with detailed profiles of key players such as Olympus, Fujifilm, and Karl Storz [5][6][7] - The report discusses the pricing trends of high-definition electronic bronchoscopes, providing insights into market dynamics and competitive pricing strategies [4][5][6] Group 4 - The report includes an analysis of the upstream raw materials and downstream market for high-definition electronic bronchoscopes, highlighting supply chain dynamics [8][9] - Industry opportunities and driving factors are identified, along with potential challenges and risks facing the high-definition electronic bronchoscope market [8][9][10] - A SWOT analysis of Chinese enterprises in the high-definition electronic bronchoscope sector is presented, offering insights into competitive positioning and strategic opportunities [8][9][10]

上海市通力律师事务所关于上海澳华内镜股份有限公司 2025 年第一次临时股东大会的法律意见书 致:上海澳华内镜股份有限公司 上海市通力律师事务所(以下简称"本所")接受上海澳华内镜股份有限公司(以 下简称"公司"）的委托,指派本所茹秋乐律师、赵伯晓律师(以下简称"本所律师"） 根据《中华人民共和国公司法》《中华人民共和国证券法》等法律法规和规范性文件(以 下统称"法律法规")及《上海澳华内镜股份有限公司章程》(以下简称"公司章程") 的规定就公司 2025 年第一次临时股东大会(以下简称"本次股东大会")相关事宜出 具法律意见。 本所律师已经对公司提供的与本次股东大会有关的法律文件及其他文件、资料予以 了核查、验证。在进行核查验证过程中,公司已向本所保证,公司提供予本所之文件中 的所有签署、盖章及印章都是真实的,所有作为正本提交给本所的文件都是真实、准确、 完整和有效的,且文件材料为副本或复印件的,其与原件一致和相符。 在本法律意见书中,本所仅对本次股东大会召集和召开的程序、出席本次股东大会 人员资格和召集人资格及表决程序、表决结果是否符合法律法规和公司章程的规定发表 意见,并不对本次股东大会所审议的议案内容 ...

证券代码：688212 证券简称：澳华内镜 公告编号：2025-044 上海澳华内镜股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 6 月 6 日 （二） 股东大会召开的地点：上海市闵行区光中路 133 弄 66 号澳华内镜大厦十 楼会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 218 | | --- | --- | | 普通股股东人数 | 218 | | 2、出席会议的股东所持有的表决权数量 | 47,814,550 | | 普通股股东所持有表决权数量 | 47,814,550 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 43.3495 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 43.349 ...

Group 1 - The A-share market showed volatility on June 5, with the pharmaceutical sector experiencing a slight pullback, while the Kexin Pharmaceutical Index ETF (588700) fell by 0.68% with a turnover rate exceeding 7% and a premium/discount rate of 0.10% [1] - The Kexin Pharmaceutical Index ETF closely tracks the Shanghai Stock Exchange Science and Technology Innovation Board Biopharmaceutical Index, which selects 50 large-cap companies in biopharmaceuticals, biomedical engineering, biopharmaceuticals, and other related fields [1] - Year-to-date, the Kexin Pharmaceutical Index ETF has achieved a cumulative increase of 24% as of the latest closing date [1] Group 2 - According to the outlook from交银国际, 2025 is expected to be a pivotal year for the pharmaceutical industry, with short-term policy disturbances clearing up and more favorable policies anticipated in the second half of 2025 [2] - The industry is projected to experience strong high growth in profitability over the next two years, with short-term profit forecasts being gradually revised upward [2] - The recent collaboration between三生制药 and Pfizer for a PD-1/VEGF dual antibody deal, which includes a $1.25 billion upfront payment, has set a record for domestic innovative drug overseas transactions, fueling investment enthusiasm in innovative drugs [2]

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5] Core Insights - The blood purification device industry is benefiting from an aging population and increasing treatment penetration rates, with hemodialysis being the primary treatment for end-stage renal disease (ESRD) [2][12] - The domestic substitution trend in the blood purification device industry is accelerating, with local brands gradually rising to compete with foreign brands [2][33] - The market for blood purification devices is expected to grow significantly, driven by the increasing number of ESRD patients and the low treatment penetration rate in China compared to developed countries [17][19] Summary by Sections Market Performance - The pharmaceutical sector outperformed the overall market, with a 2.21% increase in the biopharmaceutical sector, while the overall A-share market declined by 0.05% [1][60] - The TTM price-to-earnings ratio for the biopharmaceutical sector is 34.03x, which is at the 69.61% percentile of the historical valuation over the past five years [1][67] Industry Analysis - The global ESRD patient population is projected to grow from 1113.86 million in 2023 to 1328.60 million by 2027, with a compound annual growth rate (CAGR) of 4.51% [17] - In China, the number of ESRD patients receiving dialysis treatment is significantly lower than in developed countries, indicating substantial growth potential in treatment penetration [19][30] Competitive Landscape - Foreign brands dominate the blood purification device market, with companies like Fresenius and Baxter holding significant market shares, but domestic brands are rapidly gaining ground [2][33] - Major domestic players include Weigao Blood Purification, Shandong Mountain, and Jianfan Biological, which are expanding their market presence through innovation and product development [2][41][45] Company Forecasts and Ratings - Major companies in the sector, such as Mindray Medical and WuXi AppTec, are rated as "Outperform" with strong projected earnings growth over the next few years [4][71] - Mindray Medical is expected to achieve a net profit of 116.7 billion in 2024, with a PE ratio of 23.5 [4] - WuXi AppTec is projected to have a net profit of 93.5 billion in 2024, with a PE ratio of 19.6 [4]

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5] Core Insights - The blood purification device industry is benefiting from an aging population and increasing treatment penetration rates, with hemodialysis being the primary treatment for end-stage renal disease (ESRD) [2][12] - The domestic substitution trend in the blood purification device industry is accelerating, with local brands gradually rising to compete with foreign brands [2][33] - The market for blood purification devices is expected to grow significantly, driven by the increasing number of ESRD patients and the low treatment penetration rate in China compared to developed countries [17][19] Summary by Sections Market Performance - The pharmaceutical sector outperformed the overall market, with a 2.21% increase in the biopharmaceutical sector, while the total A-share market declined by 0.05% [1][60] - The TTM price-to-earnings ratio for the biopharmaceutical sector is 34.03x, which is at the 69.61% percentile of the historical valuation over the past five years [1][67] Industry Analysis - The global ESRD patient population is projected to grow from 1113.86 million in 2023 to 1328.60 million by 2027, with a compound annual growth rate (CAGR) of 4.51% [17] - In China, the number of ESRD patients receiving dialysis treatment is significantly lower than in developed countries, indicating substantial growth potential for treatment penetration [19][30] Competitive Landscape - Foreign brands dominate the blood purification device market, with companies like Fresenius and Baxter holding significant market shares, but local brands are increasingly gaining ground [33][37] - Major domestic players include Weigao Blood Purification, Shanda Mountain, and Jianfan Biological, which are expanding their market presence through innovation and product development [33][41][45] Company Forecasts and Ratings - Major companies in the sector, such as Mindray Medical and WuXi AppTec, are rated as "Outperform" with strong projected earnings growth over the next few years [4][71] - Weigao Blood Purification is expected to generate revenue of 36.04 billion yuan in 2024, with a leading market share in blood purification devices [38][41]

Group 1 - The core viewpoint of the article highlights the performance of the Shanghai Stock Exchange Sci-Tech Innovation Board Medical Index, which has shown a 4.01% increase over the past month, a 0.74% decrease over the past three months, and a 1.94% increase year-to-date [1] - The index consists of no more than 30 listed companies in the medical field selected from the Sci-Tech Innovation Board, reflecting the overall performance of medical listed companies [1] - The index was established with a base date of December 30, 2022, and a base point of 1000.0 [1] Group 2 - The top ten weighted companies in the index include: Huitai Medical (10.98%), United Imaging (10.82%), Aibo Medical (6.74%), Yirui Technology (6.5%), Nanwei Medical (5.36%), Shengxiang Biology (4.94%), Xinmai Medical (4.68%), Haier Biomedical (4.22%), Yahui Long (3.6%), and Aohua Endoscopy (3.4%) [1] - The index's holdings are entirely composed of companies listed on the Shanghai Stock Exchange, with a 100.00% share [1] - The industry composition of the index holdings includes 45.00% in medical consumables, 33.89% in medical devices, and 21.10% in in vitro diagnostics [1] Group 3 - The index sample is adjusted quarterly, with adjustments implemented on the next trading day following the second Friday of March, June, September, and December [2] - Weight factors are adjusted in accordance with the sample adjustments, which occur at the same time as the sample adjustments [2] - In special circumstances, the index may undergo temporary adjustments, such as when a sample company is delisted or undergoes mergers, acquisitions, or splits [2]

证券代码：688212 证券简称：澳华内镜 公告编号：2025-043 上海澳华内镜股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/1/6 | | | | --- | --- | --- | --- | | 回购方案实施期限 | 2025 年 1 月 3 日~2026 | 年 | 1 月 2 日 | | 预计回购金额 | 10,000万元~20,000万元 | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | | | □为维护公司价值及股东权益 | | | | 累计已回购股数 | 249.91万股 | | | | 累计已回购股数占总股本比例 | 1.86% | | | | 累计已回购金额 | 9,998.69万元 | | | | 实际回购价格区间 | 36.98元/股~41.99元/股 | | | 一、回购股份的基本情况 根据《上市公司股份回购规则》《上海证券 ...